Several large pharma companies are interested in the Pharmaxis program where both of our LOXL2 inhibitors have now successfully completed Phase 1 studies and demonstrated a best in class profile,” said Gary Phillips, CEO of Pharmaxis.
Big partner join in PXS becomes multi $$$$.
IMO+DYOR.
Cheers.
- Forums
- ASX - By Stock
- Pharmaxis takes firm steps towards commercialising
Several large pharma companies are interested in the Pharmaxis...
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.87M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 1.9¢ | $4.712K | 240.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16838 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 611853 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16838 | 0.020 |
5 | 1246784 | 0.019 |
6 | 464490 | 0.018 |
4 | 1016465 | 0.017 |
5 | 484995 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 611853 | 5 |
0.023 | 281375 | 1 |
0.024 | 771883 | 5 |
0.025 | 1121967 | 6 |
0.026 | 38460 | 1 |
Last trade - 16.10pm 19/03/2024 (20 minute delay) ? |
|
|||||
Last
2.0¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
2.1¢ | 2.1¢ | 2.0¢ | 66000 | ||
Last updated 15.21pm 19/03/2024 ? |
Featured News
SNT (ASX) Chart |